Advances in Immunotherapy for Acute Myeloid Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 15 August 2026 | Viewed by 807
Special Issue Editor
Interests: acute myeloid leukemia; cancer; hematology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by molecular heterogeneity. A deeper understanding of the immunobiology of acute myeloid leukemia is driving the development of innovative treatment strategies. Immunotherapy is considered a highly attractive strategy for controlling and eliminating the disease. In recent years, a variety of treatment protocols for AML, based on immune-mediated therapeutic mechanisms, have been developed.
We are pleased to invite you to contribute to this Special Issue entitled "Advances in Immunotherapy for Acute Myeloid Leukemia". This Special Issue aims to shed light on current pitfalls and areas of improvement of immunotherapy for AML.
In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the development of immunotherapy for AML (Antibody-Based Therapy, Immune Checkpoint Inhibitors, CAR-T Cell Therapy, etc.)
I look forward to receiving your contributions.
Dr. Pau Montesinos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia
- immunotherapy
- immune response
- T-cell
- cellular therapies
- immune checkpoint inhibitors
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
